Case Report

Endoprosthetic Reconstruction for a Displaced Atypical Femoral Fracture in a Cancer Patient with Poor Prognosis

Hironari Tamiya,1,2 Hiroki Hagizawa,2 Takaaki Nakai,2 Yoshinori Imura,2 Takaaki Tanaka,2 Kazuya Oshima,2 Toshikazu Ito,3 Norifumi Naka,2 and Shigeyuki Kuratsu1

1Department of Orthopedic Surgery, Bellland General Hospital, 500-3 Higashiyama, Naka-ku, Sakai, 599-8247 Osaka, Japan
2Department of Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka City, 541-8567 Osaka, Japan
3Department of Surgery, Rinku General Medical Center, 2-23 Rinku Ourai Kita, Izumisano, 598-8577 Osaka, Japan

Correspondence should be addressed to Hironari Tamiya; tamiya-hi@mc.pref.osaka.jp

Received 22 April 2018; Accepted 28 August 2018; Published 20 September 2018

Copyright © 2018 Hironari Tamiya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Zoledronate or denosumab treatment is beneficial for cancer patients with bone metastasis. However, each agent may trigger atypical femoral fractures. Incomplete atypical femoral fractures can be successfully treated with prophylactic intramedullary nailing. On the other hand, intramedullary nailing for displaced atypical femoral fractures occasionally causes problems with regard to bone healing, resulting in long-term treatment. In cancer patients with poor prognosis who experience atypical femoral fractures, improvement in activities of daily living should be the priority. Thus, we performed endoprosthetic reconstruction for a displaced atypical femoral fracture in a breast cancer patient with poor prognosis to enable walking in the early stage after the operation. Two weeks after the operation, she could successfully walk. The postoperative Musculoskeletal Tumor Society score was 47%, and it had improved to almost the preoperative level before injury (50%). In conclusion, endoprosthetic reconstruction for displaced atypical femoral fractures may be a first-line treatment approach to acquire early postoperative walking ability for improving activities of daily living in cancer patients with poor prognosis.

1. Introduction

Although bisphosphonates (BPs) are widely used for osteoporosis, zoledronate, which is a BP, is commonly used to reduce the occurrence of skeletal system-related events in metastatic bone disease. In addition, the anti-RANKL monoclonal antibody denosumab is used for bone metastasis. Zoledronate and denosumab are categorized as bone-modifying agents (BMAs) that effectively inhibit bone destruction by osteoclasts activated via metastatic bone tumors [1]. However, adverse effects, such as BP-related osteonecrosis of the jaw, renal dysfunction, and hypocalcemia, have been reported. Moreover, several clinical studies have shown that long-term administration of these agents can cause atypical femoral fractures (AFFs) [2].

AFFs are more challenging to treat than ordinary femoral fractures because of issues with bone healing. Incomplete AFFs should be prophylactically fixed with intramedullary nailing (IMN) because of the low rate of spontaneous bone healing [3]. For displaced AFFs, IMN is also considered as a standard approach; however, a previous report mentioned that the revision rate associated with delayed union was 46% [4]. Once delayed union/nonunion occurs, nonweight bearing is required for a long time. Furthermore, implant breakage can occur if the fracture site is overloaded under excessive force. In such cases, a longer time will be required for the treatment of displaced AFFs.

Among cancer patients, life expectancy is limited in some patients, and improvement in activities of daily living (ADL)/quality of life (QOL) is a priority in these cancer patients. If
delayed union/nonunion occurs, IMN could fail because of insufficient fixation for displaced AFFs in cancer patients. Endoprosthetic reconstruction is commonly used for primary malignant tumors, and there is no concern about bone healing problems, although this procedure is more invasive and costly. We performed endoprosthetic reconstruction for a displaced AFF in a breast cancer patient with a poor prognosis, and the patient could successfully walk in the early stage after the operation. We believe that endoprosthetic reconstruction may enable early postoperative ambulation and improve ADL/QOL in cancer patients with poor prognosis.

2. Case Report

A 48-year-old woman with breast cancer underwent mastectomy (histology: invasive ductal carcinoma, histology grade 2; estrogen receptor: positive; progesterone receptor: positive; HER2: positive; Ki67: 10%, n*27/28) at the department of surgery in a previous hospital. Subsequently, she underwent chemotherapy with paclitaxel and doxorubicin and hormonal therapy with tamoxifen. Six years after surgery, bone metastasis was noted in the vertebra, and she was treated with a combination of radiotherapy and chemotherapy with trastuzumab. However, the metastatic disease progressed. Liver metastasis was also noted at 57 years of age, and the treatment was switched to capcitabine plus lapatinib, which was shortly discontinued because of adverse effects. Disease progression continued, although fulvestrant was also added. Eventually, she underwent chemotherapy with trastuzumab emtansine (T-DM1).

For the inhibition of bone metastasis, zoledronate was initiated at 54 years of age and was continued for 5 years until renal failure. After discontinuation of zoledronate, denosumab was used for 3 years until the detection of AFFs in both proximal femurs on the bone scintigraphy at 62 years of age (Figure 1(a)). Eventually, BMAs had been administered for 8 years. Right hip pain occurred temporarily, whereas left hip pain persisted for a long time. She experienced a left displaced femoral subtrochanteric fracture after falling at the age of 63 years (Figure 1(b)). At that point, the doctors in the previous hospital made a diagnosis of a pathological fracture caused by bone metastasis and consulted with our department for specialized treatment. After the patient was transferred to our hospital, we examined whether that fracture was due to bone metastasis, but no metastatic lesion was noted at the fracture site. In addition, radiography of the fracture area exhibited a beak on the lateral side of the fracture site associated with cortical bone sclerosis, which was characteristic of an AFF (Figure 1(b)) [5]. Considering the long-term administration of BMAs, the fractures were diagnosed as AFFs.

For treating the displaced AFF, we could select either IMN or prosthetic reconstruction. For appropriate selection, evaluation of the patient’s prognosis is required because recovery of ADL/QOL is the priority in cancer patients with limited life expectancy. The Katagiri score as a predictor of prognosis in patients with skeletal metastasis was high (Table 1(a)) [6], and similarly, the score of another scoring system for metastatic breast cancer was also high (Table 1(b)) [7]. Thus, both predicted a poor prognosis. IMN is a less invasive approach, and it might successfully induce bone healing. However, delayed union/nonunion and implant failure are possible issues. To achieve early weight bearing and avoid these issues, we performed endoprosthetic reconstruction (Zimmer Biomet, OSS Proximal Femur) on the seventh day after the injury (Figure 2(a)). Two weeks after surgery, she achieved walker-assisted gait. After subsequent rehabilitation, prophylactic IMN was performed for the right incomplete AFF (Figure 2(b)). Six months after surgery, the Musculoskeletal Tumor Society (MSTS) score recovered (47%) to almost the preoperative level (50%) before the injury (Table 2). However, she died of breast cancer 1 year and 2 months after the endoprosthetic reconstruction.

3. Discussion

BP treatment can reduce the risk of fractures in osteoporosis patients, and this benefit outweighs the disadvantage of AFFs, as the reduction in the occurrence of osteoporotic fractures is much greater than the increase in the risk of AFFs. The incidence of AFFs has been reported to be 0.55 per 1000 BP-treated patients per year [5]. Considering this rarity, some clinicians tend to overlook the importance of AFFs. The incidence of AFFs has been shown to increase around 5 years after the initiation of BPs [8]. Furthermore, changes
Table 1: Prognosis predictors for metastatic breast cancers.

(a) Revised Katagiri scoring system, which is useful for predicting bone metastatic cancers. The parameters are primary site, visceral metastases, laboratory data, ECOG performance status, previous chemotherapy, and multiple skeletal metastases. The prognosis is predicted as follows: 0–3: low risk; 4–6: intermediate risk; 7–10: high risk

| Parameter                        | Value                  | Points |
|----------------------------------|------------------------|--------|
| Primary site                     | Hormone-dependent breast cancer | 0      |
| Visceral metastases              | Liver/pleural metastasis | 2      |
| Laboratory data                  | Total bilirubin: 1.65  | 2      |
| Performance status               | PS 4                   | 1      |
| Previous chemotherapy            | Yes                    | 1      |
| Multiple skeletal metastases     | Yes                    | 1      |
| **Total**                        |                        | **7**  |

(b) An internally and externally validated prognostic score for metastatic breast cancer developed by Dr. Regierer. The parameters are metastasis-free interval, hormone receptor, and metastatic breast cancers of the liver, effusion, brain, bone, bone marrow, soft tissue, and lungs. The score predictions are as follows: 0–8: low risk; 9–14: intermediate; ≥15: high risk

| Parameter                        | Value                  | Points |
|----------------------------------|------------------------|--------|
| Metastasis-free survival         | <2 years               | 3      |
| Hormone receptor                 | Positive               | 0      |
| Liver                            | Yes                    | 7      |
| Effusion                         | Yes                    | 4      |
| Brain                            | No                     | 0      |
| Bone                             | Yes                    | 4      |
| Bone marrow                      | No                     | 0      |
| Soft tissue                      | No                     | 0      |
| Lung                             | No                     | 0      |
| **Total**                        |                        | **18** |

in the bone advance gradually; hence, BPs are sometimes administered in the long term, and doctors are not aware of the occurrence of AFFs. Once AFFs occur, treatment might be difficult. Incomplete AFFs can be healed with prophylactic IMN at a high rate [3]. Displaced AFFs are more difficult to treat than incomplete AFFs. Displaced AFFs also can be treated successfully with IMN and discontinuation of BMAs; however, some earlier reports have indicated that revision was required in 46% (7/17) of patients owing to nonunion/delayed union [2] and that the mean time to bone union was 11.3 months for displaced AFFs [9]. Another report demonstrated that teriparatide (TPTD) combined with IMN is advantageous, although TPTD is contraindicated in cancer patients with bone metastasis [10]. On the other hand, hip arthroplasty after IMN breakage has been reported to provide good results [11].

Bone metastatic disease often causes intolerable pain and devastatingly impairs ADL in cancer patients. Bone metastasis can be controlled with radiotherapy and/or chemotherapy. Additionally, zoledronate, a third-generation BP, has been frequently used since its beneficial effects on skeletal system-related events were reported [8]. However, the occurrence of AFFs is associated with the long-term use of zoledronate and denosumab. Furthermore, the incidence of AFFs in cancer patients was reported to be higher than that in osteoporosis patients [5]. This previous study mentioned that more attention should be paid to AFFs in cancer patients.

Accurate diagnosis as AFFs is important to avoid over-indication of endoprosthesis. Shane et al. stated that pathological fractures are excluded in the diagnostic criteria [12]. In cancer patients, whether pathological fractures with bone metastases are difficult to identify, magnetic resonance imaging (MRI) is very helpful to differentiate AFFs from pathological fractures. In the present case, MRI was conducted and showed no metastatic lesion at the fracture site (data not shown). MRI should be taken before making the decision of the operative method.

In the present report, the patient was predicted to have a poor prognosis, and this information was used to determine the operative method. When a good prognosis is predicted, endoprosthetic reconstruction can be considered excessively invasive. Thus, reliable prediction methods for prognosis prediction are essential for the right decision. In the present study, the scoring systems advocated by Katagiri and Regierer were used, whereas PATHFx program can also provide reliable prediction [13]. With regard to the clinical outcome of endoprosthetic reconstruction for malignant tumors, the implant survival rates at 5 and 10 years were reported to be 84% and 70%, respectively, with the MSTS score of 70.8% [14]. IMN can also provide a good outcome for displaced AFFs, and the primary healing rate has been reported to be 68.7%, and the mean time to union has been reported to be 10.7 months, although there was a significant correlation between malalignment and implant failure/delayed healing time [15]. Therefore, cancer patients with a good prognosis should primarily undergo IMN with care for fracture reduction, and endoprosthetic reconstruction can be a salvage operation after implant failure. In another aspect, IMN seems to have difficulties in treating AFFs with hypertrophy of the lateral cortex associated with bowing deformity [16], which might be a good indication for endoprosthetic reconstruction.

Prognosis is an essential factor in the selection of an operative method, as mentioned above. For bone metastasis, an endoprosthesis should be used in patients with a good prognosis [17], which is in contrast to the approach for AFFs. This difference is associated with the fact that bone metastasis is malignant, whereas AFFs are not tumors. Metastatic lesions can be rarely cured despite chemotherapy and/or radiotherapy. Therefore, complete resection and endoprosthetic reconstruction are preferred when a good prognosis is predicted; otherwise, implant failure can occur at a high rate. On the other hand, displaced AFFs can be successfully treated with IMN if the patient is able to spend the time required for treatment. Thus, IMN should be first considered for patients with a relatively good prognosis. If cancer
patients with a poor prognosis undergo IMN, a long period of nonweight bearing is necessary, and patients can experience impairments in ADL/QOL. In the present patient, the postoperative MSTS score recovered to almost the preoperative level, but slightly lower. However, this result does not deny the benefit from endoprosthetic reconstruction. IMN for the present case would provide less satisfactory outcome due to nonweight bearing for a long time. Considering this disadvantage of IMN for displaced AFFs, cancer patients with limited life expectancy need to be able to walk as early as possible after the operation, and endoprosthetic reconstruction is considered a good treatment option in such patients.

4. Conclusions

IMN has been generally known as a standard method for displaced AFFs, but delayed union or nonunion is problematic. In cancer patients with poor prognosis who have displaced AFFs, improvement in ADL/QOL is the priority. Endoprosthetic reconstruction for displaced AFFs may be a first-line treatment to acquire early postoperative walking ability for improving ADL/QOL in cancer patients with limited life expectancy.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the reported case.

Acknowledgments

We thank Shusaku Umemoto who helped us in selecting an operative method and in managing the operative procedure. We also would like to thank Enago (https://www.enago.jp) for the English language review.

References

[1] X. Wang, K. H. Yang, P. Wanyan, and J. H. Tian, “Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials,” Oncology Letters, vol. 7, no. 6, pp. 1997–2002, 2014.
[2] T. Balach, P. C. Baldwin, and J. Intravia, “Atypical femur fractures associated with diphosphonate use,” Journal of the American Academy of Orthopaedic Surgeons, vol. 23, no. 9, pp. 550–557, 2015.

[3] C. W. Oh, J. K. Oh, K. C. Park, J. W. Kim, and Y. C. Yoon, “Prophylactic nailing of incomplete atypical femoral fractures,” The Scientific World Journal, vol. 2013, Article ID 450148, 4 pages, 2013.

[4] Y. A. Weil, G. Rivkin, O. Safran, M. Liebergall, and A. J. Foldes, “The outcome of surgically treated femur fractures associated with long-term bisphosphonate use,” The Journal of Trauma: Injury, Infection, and Critical Care, vol. 71, no. 1, pp. 186–190, 2011.

[5] E. Donnelly, A. Saleh, A. Unnanuntana, and J. M. Lane, “Atypical femoral fractures: epidemiology, etiology, and patient management,” Current Opinion in Supportive and Palliative Care, vol. 6, no. 3, pp. 348–354, 2012.

[6] H. Katagiri, R. Okada, T. Takagi et al., “New prognostic factors and scoring system for patients with skeletal metastasis,” Cancer Medicine, vol. 3, no. 5, pp. 1359–1367, 2014.

[7] A. C. Regierer, R. Wolters, M. P. Ufen et al., “An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients,” Annals of Oncology, vol. 25, no. 3, pp. 633–638, 2014.

[8] G. N. Hortobagyi, R. L. Theriault, L. Porter et al., “Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases,” The New England Journal of Medicine, vol. 335, no. 24, pp. 1785–1792, 1996.

[9] Y. Zenke, S. Ikeda, F. Fukuda et al., “Study of atypical femoral fracture cases coupled in a multicenter study,” Journal of UOEH, vol. 38, no. 3, pp. 207–214, 2016.

[10] S. R. Mastaglia, G. Aguilar, and B. Oliveri, “Teriparatide for the rapid resolution of delayed healing of atypical fractures associated with long-term bisphosphonate use,” European Journal of Rheumatology, vol. 3, no. 2, pp. 87–90, 2016.

[11] Y. Ozaki, T. Baba, H. Ochi et al., “Total hip arthroplasty for implant rupture after surgery for atypical subtrochanteric femoral fracture,” Case Reports in Orthopedics, vol. 2016, Article ID 7146419, 4 pages, 2016.

[12] E. Shane, D. Burr, B. Abrahamsen et al., “Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research,” Journal of Bone and Mineral Research, vol. 29, no. 1, pp. 1–23, 2014.

[13] A. Piccioli, M. S. Spinelli, J. A. Forsberg et al., “How do we estimate survival? External validation of a tool for survival estimation in patients with metastatic bone disease—decision analysis and comparison of three international patient populations,” BMC Cancer, vol. 15, no. 1, p. 424, 2015.

[14] S. Thambapillai, R. Dimitriou, K. G. Makridis, E. M. Frakakis, P. Bobak, and P. V. Giannoudis, “Implant longevity, complications and functional outcome following proximal femoral arthroplasty for musculoskeletal tumors: a systematic review,” Journal of Arthroplasty, vol. 28, no. 8, pp. 1381–1385, 2013.

[15] J. W. Cho, C. W. Oh, F. Leung et al., “Healing of atypical subtrochanteric femur fractures after cephalomedullary nailing: which factors predict union?,” Journal of Orthopaedic Trauma, vol. 31, no. 3, pp. 138–145, 2017.